Trametinib Presents Potential New Standard-of-Care for Low-Grade Serous Ovarian Carcinoma
February 7th 2022Trametinib emerged as a novel therapeutic approach for low-grade serous carcinoma due to a high prevalence of activating mutations in the mitogen-activated protein kinase signaling pathway.
Read More